Licensees

Innovate, Enhance and Lead with Invisicare.

Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals, Inc. ("Quoin") (NASDAQ: QNRX) has an exclusive, royalty-bearing license to Skinvisible's technology for select Orphan Rare Skin Diseases and a number of CNS related indications. Currently FDA clinical trials are underway for "QRX003," powered by Skinvisible's Invisicare® proprietary drug delivery technology, to address the challenges of Netherton Syndrome. Skinvisible received $1 million upfront license fee and will receive $5 million and on-going royalties upon Quoin receiving FDA / EU approval. Click Rare Skin Diseases to learn more about Skinvisible’s licensed formulations and Quoin’s initial Phase 3 results for QRX003 for Netherton Syndrome.

Rare Skin Diseases

Womens Choice Pharmaceuticals

Womens Choice Pharmaceuticals, a division of ITF Pharma, licensed Skinvisible's topical formulation powered by its Invisicare technology for the prescription treatment for hemorrhoids. Invisicare enhances the delivery of active ingredients by controlling the release and providing superior binding properties. ProCort® is made of a combination of hydrocortisone acetate and pramoxine hydrochloride. Skinvisible has been receiving on-going royalties for ProCort since 2011.

Ovation Science Inc.

Skinvisible signed an exclusive licensing agreement with Ovation Science Inc. (CSE:OVAT) for the use of its Invisicare polymers for cannabis, hemp and hemp seed oil products. In addition, Ovation signed a license to the exclusive worldwide rights to Skinvisible's DermSafe® hand sanitizer made with chlorhexidine gluconate

PARTNERSHIPS AND LICENSING OPPORTUNITIES

Partner With Us:
Skinvisible is seeking strategic partners and licensees for our innovative Invisicare formulations.

Contact Business
Development

News & Press

Releases

ovation-corporate
September 18, 2025

Ovation Science and Skinvisible Strengthen Partnership in Obesity Market with New Cannabinoid Delivery Patents

Ovation Science and Skinvisible Pharmaceuticals have expanded their partnership to advance patent-pending Invisicare® cannabinoid delivery technology for obesity and metabolic health. The collaboration leverages THC-V research, new patent protection, and the growing US$150B obesity therapy market.
Read more
Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies
January 23, 2025

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Skinvisible Pharmaceuticals announces major progress in 2024-2025 through its licensee, Quoin Pharmaceuticals, in developing QRX003 for Netherton Syndrome using Invisicare technology. With FDA clearance, global clinical trials, and regulatory success, Skinvisible advances innovative topical and transdermal therapies.
Read more
Skinvisible Proprietary Transdermal Obesity Formulation Development 2025
October 3, 2024

Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development

Skinvisible Pharmaceuticals publishes groundbreaking research on transdermal obesity drug delivery using Invisicare technology. The study shows 99.6% transdermal penetration of GLP-1 actives, offering a non-invasive alternative to injections. Skinvisible seeks partnerships to bring transdermal obesity therapies to market.
Read more
Promising Data on Transdermal Obesity Formulations
July 9, 2024

Skinvisible Unveils Promising Data on Transdermal Obesity Formulations

Skinvisible Pharmaceuticals announces breakthrough data on transdermal obesity drug delivery using Invisicare technology. Studies show up to 69% drug penetration, offering a non-invasive alternative to injections. Skinvisible seeks partners to bring transdermal obesity therapies to market.
Read more
Obesity Patent Application for Transdermal Delivery
June 24, 2024

Skinvisible Expands Obesity Patent Application for Transdermal Delivery

Skinvisible Pharmaceuticals expands its obesity patent application for transdermal drug delivery using Invisicare technology. The innovation enhances systemic absorption of GLP-1 agonists, CB-1 antagonists, and SGLT-2 inhibitors, offering a needle-free alternative. Skinvisible seeks partners to bring this breakthrough to market.
Read more
Obesity Patent for Advanced Transdermal Treatment
May 29, 2024

Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment

Skinvisible Pharmaceuticals files a provisional patent for transdermal obesity drug delivery using Invisicare technology. This needle-free, topical solution enhances drug absorption and patient compliance, revolutionizing obesity treatment. Skinvisible seeks partners to bring this innovation to market.
Read more